Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: Insight into chemobrain

References

• Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 2001; 122: 945–962
   PubMed Web of Science ®Google Scholar
• Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol 1997; 10: 485–494
   PubMed Web of Science ®Google Scholar
• Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995; 65: 2146–2156
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19: 33–36
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002; 32: 1050–1060
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548–554
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002; 33: 562–571
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002; 82: 1524–1532
   PubMed Web of Science ®Google Scholar
• Lauderback CM, Drake J, Zhou D, Hackett JM, Castegna A, Kanski J, Tsoras M, Varadarajan S, Butterfield DA. Derivatives of xanthic acid are novel antioxidants: Application to synaptosomes. Free Radic Res 2003; 37: 355–365
   PubMed Web of Science ®Google Scholar
• Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracycline analogs: The past, present, and future. Cancer Chemother Pharmacol 1986; 18: 185–197
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998; 55: 5–30
   PubMed Web of Science ®Google Scholar
• Cummings J, Anderson L, Willmott N, Smyth JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 1991; 27: 532–535
   PubMed Web of Science ®Google Scholar
• Chuang RY, Chuang LF. Inhibition of chicken myeloblastosis RNA polymerase II activity by adriamycin. Biochemistry 1979; 18: 2069–2073
   PubMed Web of Science ®Google Scholar
• Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G–T and A–C substitutions. J Biol Chem 1992; 267: 166–172
   PubMed Web of Science ®Google Scholar
• Gutierrez PL. The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: A review. Free Radic Biol Med 2000; 29: 263–275
   PubMed Web of Science ®Google Scholar
• Kappus H. Oxidative stress in chemical toxicity. Arch Toxicol 1987; 60: 144–149
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672–1677
   PubMed Web of Science ®Google Scholar
• DeAtley SM, Aksenov MY, Aksenova MV, Carney JM, Butterfield DA. Adriamycin induces protein oxidation in erythrocyte membranes. Pharmacol Toxicol 1998; 83: 62–68
   PubMedGoogle Scholar
• DeAtley SM, Aksenov MY, Aksenova MV, Harris B, Hadley R, Cole Harper P, Carney JM, Butterfield DA. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett 1999; 136: 41–46
   PubMed Web of Science ®Google Scholar
• Yen HC, Oberley TD, Gairola CG, Szweda LI, St Clair DK. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 1999; 362: 59–66
   PubMed Web of Science ®Google Scholar
• Davies KJ, Doroshow JH, Hochstein P. Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5-iminodaunorubicin. FEBS Lett 1983; 153: 227–230
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983; 43: 4543–4551
   PubMed Web of Science ®Google Scholar
• Handa K, Sato S. Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gann 1975; 66: 43–47
   PubMedGoogle Scholar
• Gutteridge JM. Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex. Biochem Pharmacol 1984; 33: 1725–1728
   PubMed Web of Science ®Google Scholar
• Abali H, Celik I. High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel. Am J Clin Oncol 2002; 25: 632–633
   PubMedGoogle Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Sultana R, Newman S, Mohmmad-Abdul H, Keller JN, Butterfield DA. Protective effect of the xanthate, D609, on Alzheimer's amyloid beta-peptide (1–42)-induced oxidative stress in primary neuronal cells. Free Radic Res 2004; 38: 449–458
   PubMed Web of Science ®Google Scholar
• Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Abeta1-42. J Neurochem 2001; 78: 413–416
   PubMed Web of Science ®Google Scholar
• Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, Butterfield DA. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 1997; 69: 1161–1169
   PubMed Web of Science ®Google Scholar
• van der Vliet A, Eiserich JP, Kaur H, Cross CE, Halliwell B. Nitrotyrosine as biomarker for reactive nitrogen species. Methods Enzymol 1996; 269: 175–184
   PubMed Web of Science ®Google Scholar
• Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999; 1461: 359–376
   PubMed Web of Science ®Google Scholar
• Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: Implications for accumulation of reactive lipid peroxidation products. Neurochem Res 2004; 29: 2215–2220
   PubMed Web of Science ®Google Scholar
• Kienzl E, Jellinger K, Stachelberger H, Linert W. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?. Life Sci 1999; 65: 1973–1976
   PubMedGoogle Scholar
• Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: Inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 2003; 63: 849–861
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Morehouse KM, Mason RP. An electron paramagnetic resonance study of the interactions between the adriamycin semiquinone, hydrogen peroxide, iron-chelators, and radical scavengers. Arch Biochem Biophys 1991; 286: 164–170
   PubMed Web of Science ®Google Scholar
• Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23: 23–34
   PubMed Web of Science ®Google Scholar
• Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA, Jr., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997; 36: 11293–11297
   PubMed Web of Science ®Google Scholar
• Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol 1996; 271: H2079–H2085
   PubMed Web of Science ®Google Scholar
• Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 1999; 368: 421–428
   PubMed Web of Science ®Google Scholar
• Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261: 3060–3067
   PubMed Web of Science ®Google Scholar
• Cooper A. Glutathione in brain: Disorder of glutathione metabolism. The molecular and genetic basis of neurological disease. Butterwort-Heinemann, Newton, MA 1997; 1195–1230
   Google Scholar
• Abd El-Gawad HM, El-Sawalhi MM. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: Role of aminoguanidine. J Biochem Mol Toxicol 2004; 18: 69–77
   PubMed Web of Science ®Google Scholar
• Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275: 33585–33592
   PubMed Web of Science ®Google Scholar
• Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609–1623
   PubMed Web of Science ®Google Scholar
• Vasquez-Vivar J, Hogg N, Martasek P, Karoui H, Tordo P, Pritchard KA, Jr, Kalyanaraman B. Effect of redox-active drugs on superoxide generation from nitric oxide synthases: Biological and toxicological implications. Free Radic Res 1999; 31: 607–617
   PubMed Web of Science ®Google Scholar
• Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. Peroxynitrite-induced alterations in synaptosomal membrane proteins: Insight into oxidative stress in Alzheimer's disease. J Neurochem 1999; 72: 310–317
   PubMed Web of Science ®Google Scholar
• Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092–2097
   PubMed Web of Science ®Google Scholar
• Xie C, Lovell MA, Markesbery WR. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radic Biol Med 1998; 25: 979–988
   PubMed Web of Science ®Google Scholar
• Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 1997; 68: 255–264
   PubMed Web of Science ®Google Scholar
• Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004; 129: 349–360
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994; 54: 4833–4836
   PubMed Web of Science ®Google Scholar
• Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996; 271: 9675–9682
   PubMed Web of Science ®Google Scholar
• Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, Miller DW. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 1998; 243: 816–820
   PubMed Web of Science ®Google Scholar
• Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96: 3900–3905
   PubMed Web of Science ®Google Scholar
• Decleves X, Regina A, Laplanche JL, Roux F, Boval B, Launay JM, Scherrmann JM. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci Res 2000; 60: 594–601
   PubMed Web of Science ®Google Scholar
• Hirrlinger J, Konig J, Keppler D, Lindenau J, Schulz JB, Dringen R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 2001; 76: 627–636
   PubMed Web of Science ®Google Scholar
• Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 1998; 247: 859–863
   PubMed Web of Science ®Google Scholar